Home / News (Page 2)

News

FDA approval to launch INVAC-1 Phase II clinical trial

Invectys announces FDA approval to launch a Phase II clinical trial of its therapeutic cancer vaccine INVAC-1 After a recent capital raise of 4.3 M€s another…

Read more

4,3 Millions d’Euros de levés pour initier la Phase II

After its Phase I success, Invectys raises €4.3 million to enter Phase II with both of its anti-cancer vaccines   Paris, July 12th, 2017 – This round brings…

Read more

Invectys presents its INVAC-1 therapeutic vaccine Phase...

Presentation of the Invectys clinical trial results on cancer patients at the most important worldwide oncology meeting taking place this year in Chicago, USA Paris,…

Read more

Invectys at the Third International Symposium on Immuno...

Invectys at the Third International Symposium on Immunotherapy organised by The Institute for Cancer Vaccines & Immunotherapy (previously known as the Cancer…

Read more

Invectys at ASCO 2017 in Chicago : Clinical Oncology

Invectys attend ASCO 2017 meeting in Chicago  Invectys will be at the Annual Meeting is organized by American Society Of Clinical Oncology (ASCO). This meeting…

Read more

10th European Life Sciences Forum SachsForum (ELSCEO), ...

Invectys will attend the Sachs Forum in Zürich, 6. March –  7. March 2017   Meet Invectys there ! More information:  invest@invectys.com The 10th…

Read more

Invectys was at J.P. Morgan Conference in San Francisco

J.P. Morgan 35Th Annual Healthcare Conference 2017 San-Francisco…

Read more

Medicen et Invectys: success of the TelVac project

Medicen Paris Region et Invectys annoncent le succès du projet TelVac pour la recherche d’un candidat vaccin contre le cancer…

Read more